静态FET PET影像组学用于鉴别胶质瘤治疗相关变化与肿瘤进展
研究纳入151例组织学确诊胶质瘤且治疗后MRI进展的患者,用O-(2-[18F]氟乙基)-L-酪氨酸(FET)PET静态数据构建影像组学模型鉴别治疗相关变化(TRC)与肿瘤进展(TP)。联合常规FET PET参数与两个影像组学特征的模型在验证集AUC 0.92、独立测试集AUC 0.85,显示较高诊断准确性。
要点
- 151例胶质瘤治疗后MRI进展患者接受动态FET PET扫描,其中124例用于模型开发与验证,27例用于独立测试。
- 常规FET PET参数TBRmean和TBRmax模型在验证集与测试集AUC均为0.78,敏感度64%、特异度80%。
- 联合常规FET PET参数与两个影像组学特征的模型验证集AUC 0.92、测试集AUC 0.85。
核心结论
- 所开发的影像组学分类器基于常规采集的静态FET PET扫描,可在治疗后的胶质瘤中以较高诊断准确性鉴别TRC与TP。
研究设计与样本
- 回顾性分析151例组织学确诊胶质瘤且按神经肿瘤学反应评估标准出现治疗后MRI进展的患者,均接受O-(2-[18F]氟乙基)-L-酪氨酸(FET)动态氨基酸PET扫描。
- 124例在独立PET扫描仪上检查,数据用于模型开发与验证;27例在PET/MRI混合扫描仪上检查,数据用于模型测试。
- 采用注射后20至40分钟的PET数据计算平均和最大肿瘤与脑比值(TBRmean、TBRmax),并评估逻辑回归模型。
主要发现
- 37例(25%)诊断为TRC,114例(75%)为TP。
- 包含常规FET PET参数TBRmean和TBRmax的逻辑回归模型在验证集AUC为0.78(敏感度64%,特异度80%),在测试集AUC为0.78(敏感度64%,特异度80%)。
- 联合常规FET PET参数与两个影像组学特征的模型在验证集诊断性能最佳(AUC 0.92,敏感度91%,特异度80%),并在独立测试集显示泛化性(AUC 0.85,敏感度81%,特异度70%)。
关键数值与推荐
- 常规FET PET参数模型:验证集AUC 0.78(敏感度64%,特异度80%);测试集AUC 0.78(敏感度64%,特异度80%)。
- 联合常规FET PET参数与两个影像组学特征的模型:验证集AUC 0.92(敏感度91%,特异度80%);测试集AUC 0.85(敏感度81%,特异度70%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the potential of radiomics applied to static clinical PET data using the tracer O-(2-[18F]fluoroethyl)-L-tyrosine (FET) to differentiate treatment-related changes (TRC) from tumor progression (TP) in patients with gliomas. PATIENTS AND METHODS: One hundred fifty-one (151) patients with histologically confirmed gliomas and post-therapeutic progressive MRI findings according to the response assessment in neuro-oncology criteria underwent a dynamic amino acid PET scan using the tracer O-(2-[18F]fluoroethyl)-L-tyrosine (FET). Thereof, 124 patients were investigated on a stand-alone PET scanner (data used for model development and validation), and 27 patients on a hybrid PET/MRI scanner (data used for model testing). Mean and maximum tumor to brain ratios (TBRmean, TBRmax) were calculated using the PET data from 20 to 40 min after tracer injection. Logistic regression models were evaluated for the FET PET parameters TBRmean, TBRmax, and for radiomics features of the tumor areas as well as combinations thereof to differentiate between TP and TRC. The best performing models in the validation dataset were finally applied to the test dataset. The diagnostic performance was assessed by receiver operating characteristic analysis. RESULTS: Thirty-seven patients (25%) were diagnosed with TRC, and 114 (75%) with TP. The logistic regression model comprising the conventional FET PET parameters TBRmean and TBRmax resulted in an AUC of 0.78 in both the validation (sensitivity, 64%; specificity, 80%) and the test dataset (sensitivity, 64%; specificity, 80%). The model combining the conventional FET PET parameters and two radiomics features yielded the best diagnostic performance in the validation dataset (AUC, 0.92; sensitivity, 91%; specificity, 80%) and demonstrated its generalizability in the independent test dataset (AUC, 0.85; sensitivity, 81%; specificity, 70%). CONCLUSION: The developed radiomics classifier allows the differentiation between TRC and TP in pretreated gliomas based on routinely acquired static FET PET scans with a high diagnostic accuracy.
引用
- Müller M, Winz O, Gutsche R, et al. Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression. J Neurooncol. 2022. PMID: 35852737. doi:10.1007/s11060-022-04089-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。